Diana Ernst, RPh

Editorial Director

Diana Ernst, RPh, is the Editorial Director for MPR, part of the Haymarket Medical Network. Since 2003, Diana has worked to provide healthcare professionals with up-to-date drug information through MPR's print and digital offerings. She is a graduate of the Ernest Mario School of Pharmacy, Rutgers University.

All articles by Diana Ernst, RPh

Lung Infection

Study to Assess Antiviral Antibody Cocktail for COVID-19 Prevention Begins

Diana Ernst, RPh

July 10, 2020

A phase 3 trial evaluating an investigational antiviral antibody cocktail, REGN-COV2, for the prevention of COVID-19 has been initiated by Regeneron Pharmaceuticals.

Lung Infection

FDA Issues Guidance for COVID-19 Vaccine Development

Diana Ernst, RPh

July 7, 2020

The FDA has issued guidance to assist in the development and licensure of vaccines for the prevention of COVID-19.

General Pulmonology

Tacrolimus Inhalation Powder Gets Orphan Drug Status for Organ Rejection Prophylaxis

Diana Ernst, RPh

June 24, 2020

The FDA has granted Orphan Drug Designation to Tacrolimus Inhalation Powder (TFF Pharmaceuticals) for prophylaxis of lung allograft rejection.

Asthma

Dupilumab Prefilled Pen Approval Provides Additional Administration Option

Diana Ernst, RPh

June 24, 2020

The FDA has approved a prefilled pen formulation of Dupixent (dupilumab; Sanofi and Regeneron), providing another option for administering the treatment.

Lung Cancer

Lurbinectedin Approved for Metastatic Small Cell Lung Cancer

Diana Ernst, RPh

June 23, 2020

The FDA has approved lurbinectedin for the treatment of adult patients with metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy.

Lung Infection

FDA Revokes EUA for COVID-19 Antibody Test, Cracks Down on Fraudulent At-Home Tests

Diana Ernst, RPh

June 23, 2020

Warning letters have been issued to 3 companies marketing adulterated and misbranded serological tests that claim to detect antibodies to severe acute respiratory syndrome coronavirus 2.

Lung Infection

FDA: Coadministration of Remdesivir With Chloroquine or Hydroxychloroquine Not Recommended

Diana Ernst, RPh

June 19, 2020

The antiviral activity of remdesivir, an investigational treatment for COVID-19, may potentially be reduced if it is coadministered with chloroquine or hydroxychloroquine, according to the FDA.

Lung Infection

FDA: Emergency Use Authorization Revoked for Chloroquine, Hydroxychloroquine

Diana Ernst, RPh

June 18, 2020

The FDA has revoked the emergency use authorization for chloroquine phosphate and hydroxychloroquine sulfate based on emerging data suggesting that these agents are unlikely to be effective against COVID-19.

Lung Infection

NICHD Study to Examine Drugs Used to Treat Pediatric COVID-19

Diana Ernst, RPh

June 12, 2020

Unlike a clinical trial with a control group, the study will focus on collecting data in order to identify appropriate and safe doses; it will not be evaluating the best treatment for COVID-19.

Lung Infection

Early Data Show Potential Benefit of Acalabrutinib in Severe COVID-19

Diana Ernst, RPh

June 11, 2020

Acalabrutinib, a Bruton tyrosine kinase inhibitor, appears to reduce respiratory distress as well as the hyperinflammatory immune response associated with coronavirus disease 2019.

Next post in Lung Infection